Peptide and compounding law · Updated

Opening a peptide clinic in North Carolina: the legal checklist

Opening a peptide clinic in North Carolina is mostly a medical-practice project, not a product one. Before the first patient a clinic needs: a practice entity owned by North Carolina licensees and registered with the Medical Board, with any outside investor on the management side; a physician, or a nurse practitioner or physician assistant working under the state's supervision rules, who evaluates each patient before prescribing; every peptide from a lawful channel (an FDA-approved drug, or a 503A pharmacy compounding for that patient from an ingredient federal law allows), never "research use only" vials; pharmacies permitted to dispense in North Carolina; advertising it can substantiate; and contracts that pay no one for referrals. Federal peptide status is still moving: HHS's October 30, 2026 peptide policy is a draft.

Peptide clinic legal checklist for North Carolina (as of November 4, 2026)
StepWhat the clinic needsRule
1. The practice entityOwned entirely by holders of active North Carolina licenses, or a combination G.S. 55B-14 permits; a professional corporation gets a Medical Board certificate of registration before it files with the Secretary of StateNCMB, corporate practice of medicine (amended Sept. 2025); 21 NCAC 32C .0103
2. Investors and managementA non-licensee owns a management company, not the practice; its fee is not a percentage of the practice's revenueNCMB, referral fees and fee splitting (amended Sept. 2021)
3. CliniciansA North Carolina-licensed physician; a nurse practitioner with a collaborative practice agreement approved by both boards; a physician assistant with a supervisory arrangement on file at each site21 NCAC 32M .0104, .0110; 21 NCAC 32S .0213
4. Before any prescriptionAn appropriate history and physical examination, or in telemedicine enough information for a reasonably presumptive treatment plan; not a questionnaire aloneNCMB, contact with patients before prescribing (amended July 2024); NCMB, telemedicine (amended Mar. 2024)
5. Every product's sourceAn FDA-approved drug on prescription, or a 503A compound for an identified patient from an eligible ingredient; no "research use only" products21 U.S.C. 353a; Are peptides legal?
6. PharmaciesCompounded drugs only on a valid prescription; office use only as federal law permits; an out-of-state pharmacy needs a Board of Pharmacy permit to ship into North Carolina21 NCAC 46 .2801; 21 NCAC 46 .1607
7. Dispensing in the clinicDrugs dispensed by a nurse practitioner or physician assistant must come from a place holding a current pharmacy permit; physicians ask the Board of Pharmacy about a dispensing permit21 NCAC 46 .1703; NCMB DEA FAQ
8. Staff who give injectionsDelegation only to a trained, qualified person under appropriate supervision; nurses delegate to unlicensed staff only tasks meeting the Board of Nursing's five criteriaNCMB on delegation; 21 NCAC 36 .0221
9. Controlled substancesA DEA registration only if the clinic prescribes or dispenses a controlled substance, such as testosterone (Schedule III) or phentermine (Schedule IV)21 CFR 1301.11; 21 CFR 1308.13, 1308.14
10. MarketingClaims the clinic can substantiate; no false testimonials; its own patients' photos; never "generic" or "the same as" an approved drug for a compounded oneNCMB, advertising and publicity (amended July 2026); FTC; FDA
11. Contracts and referral paymentsMedical director, management, pharmacy and marketing agreements priced for the work, not for patients sentNCMB on G.S. 90-401; Anti-Kickback Statute guide
12. Records and privacyHIPAA compliance if the clinic transmits health information electronically in a standard transaction; written business associate agreements45 CFR 160.103; 45 CFR 164.502(e)

1. The entity: who may own a peptide clinic

A clinic that evaluates patients and prescribes peptides is practicing medicine, whatever it calls itself. The Medical Board's position on the corporate practice of medicine (adopted March 2016, amended September 2025) is that "businesses practicing medicine in North Carolina must be owned in their entirety by persons holding active North Carolina licenses", with listed exceptions for hospitals, HMOs, public health clinics and charitable nonprofits, and with the combinations G.S. 55B-14 permits, such as a physician together with a physician assistant or nurse practitioner (NCMB). A wellness brand owned by a non-physician founder cannot be the practice.

A professional corporation for medicine starts at the Medical Board, not the Secretary of State. The Board issues a certificate of registration, and the Board's page says the Secretary of State filing "must be completed within four months of the NCMB Certificate issued date"; the application fee is $50 (NCMB). The application includes a certificate that all shareholders are licensed, which the Board approves before the articles are filed (21 NCAC 32C .0103), and the name has to carry "P.C.", "P.A." or "P.L.L.C." and may not be "false, misleading, deceptive or patently offensive" (21 NCAC 32C .0102). More on ownership in clinics and med spas.

2. Investors and management companies

Money from outside investors usually goes into a management services organization (MSO) that owns the lease, the equipment, the brand and the staff contracts and charges the practice a fee. The fee is where these structures fail. The Medical Board's statement on referral fees and fee splitting (adopted November 1993, amended September 2021) says a licensee "cannot share revenue on a percentage basis with a non-licensee" except where the law permits it (NCMB). A flat fee at fair market value for defined services, set before it is charged, is the usual answer. How the two entities fit together is in telehealth and MSO structures.

3. Who sees the patient and writes the prescription

Before prescribing, the Medical Board expects "an informed medical judgment", which "ordinarily" means "an appropriate history and physical examination", documented. It calls prescribing "to individuals the licensee has never met based solely on answers to a set of questions" inappropriate and unprofessional; a telemedicine prescription is acceptable where the threshold information for a reasonably presumptive treatment plan has been obtained (NCMB, amended July 2024). Its telemedicine statement adds that a licensee treating a patient in North Carolina "should be licensed in North Carolina" unless an exception applies, that the Board "does not endorse a separate standard of care for telemedicine", and that licensees are expected to use the Controlled Substances Reporting System (NCMB, amended March 2024).

A nurse practitioner may perform medical acts only with "a collaborative practice agreement with a primary supervising physician", and may not practice until both the Board of Nursing and the Medical Board approve (21 NCAC 32M .0104). The agreement is signed by both, kept at each practice site, reviewed at least yearly, lists the drugs the nurse practitioner may prescribe, and comes with monthly quality meetings for the first six months and then every six months, with records kept five years (21 NCAC 32M .0110, .0109).

A physician assistant works under a signed supervisory arrangement kept at every site, with written prescribing instructions and the same meeting schedule (21 NCAC 32S .0213). Since August 1, 2026 an experienced physician assistant may practice in a "team-based" setting, which needs more than 4,000 hours of practice, a setting majority-owned by physicians and the Medical Board's authorization before starting. The Board adds that "all physician assistants who compound must be supervised by an NC licensed physician" under the traditional rules (NCMB). Whether mixing or reconstituting a peptide at the clinic counts as compounding for this purpose is not answered in the Board's page; plan the supervision as if it does.

4. Where every peptide comes from

This is the step that has changed most in 2026, and it is federal. A peptide that is an FDA-approved drug, such as semaglutide or tirzepatide in their branded forms, is prescribed like any other drug. A compounded peptide is lawful only from a pharmacy working under section 503A for an identified patient, from an ingredient the law lets it use. On October 30, 2026 HHS published a draft policy saying it does not intend to enforce against 503A compounding of six listed peptides, including BPC-157 and TB-500, under its conditions; the draft is not binding. Peptides sold "for research use only" are, in the FDA's view, unapproved new drugs when they are meant for people, and a clinic should not buy them. The detail is in Are peptides legal?, the FDA's peptide lists, 503A vs 503B, research-use-only peptides and, for GLP-1 programs, compounded tirzepatide and semaglutide.

Office stock is the trap. A 503A pharmacy compounds for a named patient; a clinic that wants vials on the shelf is asking for something 503A does not provide, and North Carolina allows compounding for a practitioner's office use only as federal law permits (21 NCAC 46 .2801).

5. Pharmacies and dispensing in the clinic

Every pharmacy that fills the clinic's prescriptions needs a North Carolina Board of Pharmacy permit to dispense into the state, including a pharmacy based in another state (21 NCAC 46 .1607). North Carolina's compounding rule lets a pharmacy dispense a compounded drug only on a valid prescription and says compounded preparations "shall not be offered to other entities for resale" (21 NCAC 46 .2801). Ask each pharmacy which section it compounds under and for its permit.

Handing a patient a vial at the clinic is dispensing, which is a separate question from prescribing. Under the Board of Pharmacy's rule, "all drugs dispensed by a nurse practitioner or physician assistant must be dispensed from a place holding a current pharmacy permit from the Board", packaged, labeled and recorded as state and federal law require (21 NCAC 46 .1703). For physicians, the Medical Board's own FAQ sends dispensing questions to the Board of Pharmacy (NCMB); settle it with that Board before the clinic dispenses anything.

6. Staff who give injections

The Medical Practice Act lets a physician delegate to a qualified person tasks "otherwise permitted by law or established by custom". The Medical Board's guidance is to delegate only if the physician is satisfied that "the individual is trained and qualified to do the task" and "the physician provides appropriate supervision", and it notes that the more invasive a task is, the less likely it is to be customarily delegated (NCMB). A nurse may delegate to unlicensed staff only tasks that recur, follow established steps, vary little between patients, have a predictable outcome and do not involve ongoing assessment; anything else "shall be performed by a licensed nurse" (21 NCAC 36 .0221). Write down who may give which injection, under whose supervision, and the training each person has had.

7. Controlled substances

No commonly sold peptide is on the federal controlled-substance schedules. A clinic needs a DEA registration only if it will prescribe, dispense or hold a controlled substance (21 CFR 1301.11); the Medical Board's FAQ puts it plainly: "DEA registration is not required to prescribe non-controlled substances" (NCMB). A clinic that also prescribes testosterone needs one: it is Schedule III as an anabolic steroid (21 CFR 1308.13), and so does one prescribing phentermine, Schedule IV (21 CFR 1308.14). A nurse practitioner prescribing them needs a DEA number on each prescription, and the supervising physician's DEA schedules must be equal to or greater than the nurse practitioner's (21 NCAC 32M .0109).

8. Marketing and front-desk sales

Three regulators read a peptide clinic's ads. The Medical Board's advertising statement, amended July 2026, treats advertising "that is deceptive, false, or misleading" as unprofessional conduct, says licensees "should be prepared to substantiate claims made in advertisements", rules out false patient testimonials, and says patient photographs "should be of the licensee's own patients and demonstrate realistic outcomes" (NCMB). The FTC requires "competent and reliable scientific evidence" for health claims about any health-related product (FTC, December 2022); in 2025 it settled charges that NextMed, which sold telehealth weight-loss programs with access to providers who could prescribe GLP-1 drugs, made unsubstantiated weight-loss claims and used "before and after photos of people who were not their customers" (a $150,000 settlement, final in December 2025; FTC). And the FDA treats describing a compounded drug "as a generic version of an FDA-approved drug or the same as a drug approved by FDA" as false or misleading (FDA, June 15, 2026).

Selling supplements or skin products at the front desk has its own rule. The Medical Board's statement on the sale of goods (amended September 2025) allows health-related goods "only after the patient has been told those or similar items can be obtained locally from other sources", with any charge reasonable and told in advance, and no non-health goods at all (NCMB).

9. Contracts and referral payments

A peptide clinic usually signs four contracts in its first month: a medical director or supervision agreement, a management agreement, a pharmacy supply arrangement and a marketing or lead-generation contract. Each should be priced for the work done, not for the patients or prescriptions it produces. The Medical Board's position is that "payment by or to a licensee solely for the referral of a patient is unethical" and that referral fees "are prohibited by state law pursuant to N.C. Gen. Stat. § 90-401" (NCMB). Where Medicare, Medicaid or another federal program pays for any part of what the clinic does, the federal Anti-Kickback Statute also applies; see the Anti-Kickback Statute for GLP-1 and peptide clinics.

10. Records, privacy and consent

A health care provider "who transmits any health information in electronic form in connection with a transaction covered by" the HIPAA rules is a covered entity (45 CFR 160.103), and its vendors that handle patient information need written business associate agreements (45 CFR 164.502(e)). A cash-only clinic that sends no electronic claims may sit outside that definition; it still has to keep the records the Medical Board expects. For treatments that are novel or off-label, the Board's statement on innovative treatment (amended May 2024) asks that information be put in writing and consent obtained when practical, and that records of the course of treatment include adverse events (NCMB).

Common questions

Do I have to be a doctor to open a peptide clinic in North Carolina?

To own the medical practice, yes, or a licensee combination G.S. 55B-14 permits, such as a physician with a physician assistant or nurse practitioner. The Medical Board's position is that a business practicing medicine must be owned entirely by holders of active North Carolina licenses. A non-licensee can own a management company that contracts with the practice for a fee that is not a share of its revenue.

Can a nurse practitioner run a peptide clinic?

Not alone. In North Carolina a nurse practitioner performs medical acts only under a collaborative practice agreement with a primary supervising physician, approved by both the Board of Nursing and the Medical Board, kept at each practice site and reviewed every year.

Can a peptide clinic prescribe after an online questionnaire?

Not on the questionnaire alone. The Medical Board calls prescribing to people the licensee has never met based solely on answers to a set of questions inappropriate and unprofessional. A telemedicine visit can support a prescription where the threshold information for a reasonably presumptive treatment plan has been obtained.

Can a clinic buy research-use-only peptides?

It should not. The FDA treats peptides labeled "research use only" as unapproved new drugs when they are meant for people, and federal cases have been built on that label. Compounded peptides come from a pharmacy working under section 503A for an identified patient.

Can medical assistants give peptide injections in North Carolina?

Only as a delegated task: the physician must be satisfied that the person is trained and qualified and must supervise appropriately, and the Medical Board notes that more invasive tasks are less likely to be customarily delegated. Nurses may delegate only tasks meeting the Board of Nursing's five criteria. Document each delegation.

Does a peptide clinic need a DEA registration?

Only if it prescribes, dispenses or holds a controlled substance. No commonly sold peptide is federally scheduled, but testosterone (Schedule III) and phentermine (Schedule IV) are, so a clinic prescribing either needs one.

Update log

  • November 4, 2026. Published. NC Medical Board position statements (corporate practice, fee splitting, prescribing, telemedicine, advertising, sale of goods, innovative treatment), its professional corporation, team-based PA and DEA FAQ pages, the NC Administrative Code rules cited (Cornell LII), the FTC guidance and NextMed releases, and the federal regulations (eCFR, as of October 30, 2026) read at the source November 4, 2026. FDA status as on the linked guides (FDA lists re-checked November 4, 2026).

Sources

Related

Published November 4, 2026; updated November 4, 2026. General information, not legal advice. See the disclaimer.

Opening a peptide, GLP-1 or longevity clinic?

DPS Law advises clinics, physicians, management companies and investors on North Carolina practice ownership, management agreements, pharmacy sourcing and advertising. For another state's medical or pharmacy board rules, talk to a lawyer licensed in that state.

Peptide attorney in Charlotte, NC